|
||||||||||||||||||||||||||||||||||
[發(fā)表評(píng)論] [本類其他產(chǎn)品] [本類其他供應(yīng)商] [收藏] |
銷售商: 上海皓元生物醫(yī)藥科技有限公司 | 查看該公司所有產(chǎn)品 >> |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
MLT-943CAS No. : 1832576-04-1
MCE 國(guó)際站:MLT-943
產(chǎn)品活性:MLT-943 是一種有效的、選擇性的、口服活性的 MALT1 protease 抑制劑。MLT-943 可抑制 PBMC 或全血中 IL-2 的分泌,PBMC 中抑制的 IC50 值為 0.07~0.09 μM,全血中抑制的 IC50 值為 0.6~0.8 μM)。MLT-943具有抗炎活性,可用于 FcgR 介導(dǎo)的炎癥研究。
研究領(lǐng)域:Metabolic Enzyme/Protease | NF-κB
作用靶點(diǎn):MALT1
In Vitro: MLT-943 shows a high potency and selectivity in vitro. MLT-943 inhibits stimulated IL-2 secretion in PBMC or in whole blood with a similar IC50 across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood).
In Vivo: MLT-943 (oral gavage; 10 mg/kg; QD) prophylactic treatment in the rat collagen-induced arthritis model suppresses anti-collagen antibody production, fully prevents paw swelling, and normalizes joint histology scores in rat model.
MLT-943 (oral gavage; 5 mg/kg; QD; 10 consecutive days) effectively inhibits MALT1 protease activity and results in a progressive reduction in the frequency of Foxp3+CD25+ Treg cells in circulating CD4+ T cells, which was maximal after 7 days of treatment. And Discontinuation of MLT-943 treatment after day 10 leads to Treg frequency progressively returning to their original values within 4 days. Suboptimal doses of MLT-943 (0.1 and 0.5 mg/kg QD; p.o.) does not impact the Treg frequency.
MLT-943 (oral gavage; 0, 5, 20 or 80 mg/kg/day; 4-13 weeks) causes a reduction in Treg and an increase in total T cell counts, in both 4- and 13-week rat toxicity studies at all dose levels. While a 4-Longer treatment induces severe immune-mediated pathology in multiple organs, with clinical onset starting around week 9 in rat.
MLT-943 (p.o. admistration; 3 mg/kg; single dose) exhibits a good PK parameters in vivo. The Cmax values are 0.7 nM and 0.5 nM, respectively in rat and mice, respectively. And the F% are 86% and 50% in rat and mice, respective.
For i.v. admistration the compound is formed in NMP:PEG200 (30/70); For p.o. admistration solution is formed in MC:Tween 80:Water (0.5:0.5:99) solution (Sourced from literature, for reference only).
相關(guān)產(chǎn)品:Mepazine hydrochloride
品牌介紹:
• MCE (MedChemExpress) 擁有數(shù)百種全球獨(dú)家化合物,我們致力于為全球科研客戶提供最新最全的高品質(zhì)小分子活性化合物;
• 10,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng)域;
• 設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級(jí)期刊及制藥專利收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供全球最新的活性化合物;
• 與世界各大制藥公司及知名科研機(jī)構(gòu)建立了長(zhǎng)期的合作。